Search for: "Lang v. Lang" Results 61 - 80 of 1,509
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
4 Sep 2023, 8:15 am by Tristan Marot
” In assessing the term “good cause” and the court’s discretion in the context of arbitration agreements, the court referenced several precedents: De Lange v Presiding Bishop for the time being of the Methodist Church of Southern Africa and another wherein the Supreme Court of Appeal clarified that, from Section 3(2) of the Act, it is evident that a court has discretion on whether to enforce an arbitration agreement. [read post]
26 Aug 2023, 9:16 am by Kluwer Patent blogger
Protective letters In the case MyStromer v Revolt Zycling (UPC_CFI_177/2023) the UPC’s local division in Düsseldorf ordered a preliminary injunction, despite the fact that Revolt had filed a protective letter. [read post]
The board’s claim construction and motivation to combine analysis were supported by the record (Shamoon v. [read post]
21 Aug 2023, 10:00 am by Ortiz Law Firm
Ovarian Cancer – with distant metastases or inoperable or unresectable Pancreatic Cancer Paraneoplastic Cerebellar Degeneration Paraneoplastic Pemphigus Patau Syndrome (Trisomy 13) Pearson Syndrome Pelizaeus-Merzbacher Disease-Classic Form Pelizaeus-Merzbacher Disease-Connatal Form Peripheral Nerve Cancer – metastatic or recurrent Peritoneal Mesothelioma Peritoneal Mucinous Carcinomatosis Perry Syndrome Phelan-McDermid Syndrome Pineoblastoma – Childhood Pleural Mesothelioma Pompe… [read post]
2 Aug 2023, 2:14 am by Kate O’Sullivan (Bristows)
On 25 July 2023, the Court of Appeal handed down its decision in Teva & Sandoz v Astellas[1] concerning the validity of Astellas’ patent to mirabegron for use in the treatment of overactive bladder (“OAB”). [read post]
30 Jul 2023, 3:05 am by Laurence Lai (Simmons & Simmons LLP)
  Country of origin: new European applications in 2022 v requests for unitary effect   On the other hand, proprietors from Asia and the US appear overall less enthusiastic relative to their proportion of European filings. [read post]
25 Jul 2023, 1:43 am by Matthieu Dhenne (Dhenne Avocats)
Or that the credibility of the technical effect is assessed at the priority or filing date (e.g., TGI Paris, October 6, 2009, RG n°07/16446, Teva v. [read post]
Comment The Court of Appeal noted that it was unfortunate that the trial judge was not referred to Hallen v Brabantia. [read post]
16 Jul 2023, 11:56 pm by Kluwer Patent blogger
“ Top 3 Kluwer Trademark Blog posts   1) Good for the Goose: Own goal for Lidl in future lookalike cases by Julius Stobbs, Amelia Sainsbury and Nirmal Trivedy “This post is the first of four looking at the decision of Smith J in Lidl & another v Tesco & another [2023] EWHC 873 (Ch). [read post]
9 Jul 2023, 10:59 am by Thomas B. Griffith
In Jones Lange LaSalle Brokerage, Inc. v. 1441 L Associates, LLC, No. 22-046, JLL represented both parties to an agreement to lease property in northwest Washington, DC. [read post]
Although the Court of Appeal was clear, in Neurim v Generics [2020] EWCA Civ 793, that deciding to uphold the lower court’s decision not to grant a pharmaceutical patent PI was based on the specific facts of that case, the Patents Court has subsequently refused two further pharmaceutical PIs (Neurim v Teva [2022] EWHC 954 (Pat) and [2022] EWHC 1641(Pat), and Novartis v Teva [2022] EWHC 959 (Ch)). [read post]
2 Jul 2023, 1:37 am by Laurence Lai (Simmons & Simmons LLP)
  Country of origin: new European applications in 2022 v opt-outs   Technology fields Looking at the first International Patent Classification of each opted-out patent or application, the IPC covering preparations for medical purposes, A61K, took the prize for first place with 22,810 cases. [read post]